Rapport Therapeutics, Inc. - Common Stock (NQ:RAPP)

Performance

52-Week Range 49.0% below 52-week high

27.02

22.0652W Low 52.9352W High

1 Week 0.3% below 1-week high

22.951W Low 27.101W High

Rapport Therapeutics, Inc. - Common Stock (RAPP) traded between $22.06 and $52.93 over the past 52 weeks and last traded at $27.02, 49.0% below its 52-week high. Over the past week it ranged between $22.95 and $27.10.

Past 12 Months

+13.9%

-10.4%

-43.4%

-29.0%

-3.9%

+6.0%

1W +$3.30

1M -$3.13

3M -$20.71

6M -$11.06

YTD -$1.09

1Y +$1.52

RAPP was +6.0% over the past year, -29.0% over six months, -3.9% year to date, +13.9% in the last week.

12 Months vs Market

RAPP

+6.0%

DIA

+9.4%

SPY

+11.2%

QQQ

+11.1%

IWM

+15.9%

Over the past 12 months RAPP returned +6.0% versus DIA (Dow) +9.4%, SPY (S&P 500) +11.2%, QQQ (Nasdaq 100) +11.1% and IWM (Russell 2000) +15.9%.

Volume & Liquidity 0.00× 3-mo avg

Today 104 3-mo avg 755.6K

729.9K

1.4M

755.6K

561.0K

YTD

471.5K

460.5K

RAPP most recently traded 104 shares against a 3-month average daily volume of 755.6K.

More News

Rapport Therapeutics to Participate in Upcoming Investor Conferences

November 03, 2026

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

November 02, 2026

Rapport Therapeutics (NASDAQ:RAPP) Beats Q1 Estimates, Guided by Strong Seizure Data and Accelerated Timelines ↗

May 07, 2026

Via Chartmill

Premarket Movers for Oct. 28, 2026: Gainers and Losers ↗

October 28, 2026

Via Chartmill

Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placement

October 28, 2026

Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement

After-Hours Market Movers for Oct. 27, 2026: Gainers and Losers ↗

October 27, 2026

Via Chartmill

October 27, 2026

Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania

Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial ↗

October 25, 2026

Via MarketBeat

Premarket Movers on Oct. 20, 2026: Gainers and Losers ↗

October 20, 2026

Via Chartmill

October 20, 2026

Rapport Therapeutics to Participate in Upcoming Investor Conferences

September 02, 2026

Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. ↗

August 31, 2026

Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program

August 24, 2026

Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update

August 05, 2026

What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors? ↗

July 12, 2026

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

May 20, 2026

Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update

May 07, 2026

Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near ↗

April 27, 2026

Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting

April 21, 2026

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

April 01, 2026

This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗

March 16, 2026

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026